Literature DB >> 2758385

Morphologic characteristics of pancreatic carcinoma with diabetes mellitus.

O Ishikawa1, H Ohhigashi, A Wada, R Tateishi, S Ishiguro, Y Okano, Y Sasaki, S Imaoka, H Koyama, T Iwanaga.   

Abstract

For 81 cases of resectable pancreatic carcinoma, the site of cancer origin, cancer histologic features, and hyperplasia in the noninvolved duct were studied in relation to diabetes. They were classified into the following three groups: (1) fasting blood sugar (FBS) of less than 120 mg/dl (Group A, 26 cases); (2) FBS of more than 120 mg/dl with less than 2-year history of diabetes (Group B, 38 cases); and (3) FBS of more than 120 mg/dl with more than a 2-year history of diabetes (Group C, 17 cases). Although neither tumor size nor tumor location differed between the three groups, both the highest resectability (47%) and the lowest rate (71%) of extrapancreatic invasion were seen in Group C. A pancreatic ductogram showed that the pattern of the main pancreatic duct was intact in 0% in Group C versus 35% in Group A (P less than 0.05). Histologically, papillary/well-differentiated adenocarcinoma was present in 35% of Group A patients versus 61% of Group B and 71% of Group C patients (P less than 0.05). Papillary hyperplasia was present in the ducts of 27% of the patients in Group A; this was significantly lower than the other two groups. Atypical duct hyperplasia was present in 47% of Group C patients; this was significantly higher than in the other two groups. It appears that cells in the main pancreatic duct are vulnerable to hyperplastic and well-differentiated cancerous changes in patients with a history of diabetes of more than 2 years duration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2758385     DOI: 10.1002/1097-0142(19890901)64:5<1107::aid-cncr2820640523>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Dissociated secretion of islet amyloid polypeptide and insulin in serum-free culture media conditioned by human pancreatic adenocarcinoma cell lines.

Authors:  F Wang; J Larsson; A Abdiu; T Gasslander; P Westermark; T E Adrian; J Permert
Journal:  Int J Pancreatol       Date:  1997-04

2.  Alteration of the Langerhans islets in pancreatic cancer patients.

Authors:  B M Schmied; A B Ulrich; H Matsuzaki; C Li; H Friess; M W Böchler; A Andron-Sandberg; T E Adrian; P M Pour
Journal:  Int J Pancreatol       Date:  2000-12

Review 3.  Diabetes mellitus: a risk factor for pancreatic cancer?

Authors:  M Yalniz; P M Pour
Journal:  Langenbecks Arch Surg       Date:  2004-04-09       Impact factor: 3.445

4.  Histometric analysis of the distal pancreas in pancreatic head cancer.

Authors:  T Yamaguchi; M Miyata; W Kamiike; Y Kobayashi; H Matsuda
Journal:  Surg Today       Date:  1997       Impact factor: 2.540

5.  Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma.

Authors:  Paul Toomey; Anthony Teta; Krishen Patel; Darrell Downs; Kenneth Luberice; Sharona Ross; Alexander S Rosemurgy
Journal:  Int J Surg Oncol (N Y)       Date:  2017-04-04

6.  Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin.

Authors:  Aleksey V Matveyenko; Sarah Dry; Heather I Cox; Artemis Moshtaghian; Tatyana Gurlo; Ryan Galasso; Alexandra E Butler; Peter C Butler
Journal:  Diabetes       Date:  2009-04-29       Impact factor: 9.461

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.